Biopharma company Alnylam Pharmaceuticals (Nasdaq:ALNY) has built a brand on its innovative RNAi therapeutics. ALNY’s focus: developing a pipeline of drugs designed to help transform lives of patients with rare diseases. These are the patients facing either limited treatment options- or therapy that is simply inadequate.
Just two years ago, Alnylam landed on Forbes’ ‘100 Most Innovative Growth Companies’ list. Founded in 2002, the Massachusetts-based biotech has hooked an $11.7 billion market cap- and rocked 37% year-over-year.
A good way to invest wisely is to follow the ‘smart money’ moves. We can see that in the latest quarter, hedge funds are quite bullish on this rare drug giant. How confident? Hedge funds boosted their positions in ALNY by a solid 1.4 million shares.
That includes Roberto Mignone (Profile & Portfolio Activity) of Bridger Management, who lifted his hedge fund firm’s position nearly 17%. Worthy of note, Bridger Management is ranked #22 out of over 200 hedge funds we cover on TipRanks.
ALNY’s Galactic Opportunity
On the ALNY website, the team proudly says its pipeline stands to help the very patients that “shouldn’t have to wait for hope.” To the bears that call this pursuit “impossible, impractical, unrealistic,” ALNY is “relentless” in this pursuit to change lives.
ALNY’s investigational RNAi therapeutics are keyed into diseases with significant unmet medical needs. Specifically, the company puts its pipeline under four umbrellas called Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS) diseases.
Notably, ALNY was named after Alnilam, a star in Orion’s belt. The company has also had other nods at its origin, including an ORION-1 trial evaluating its novel injectable drug Inclisiran. The results: 1) data reveals the drug dials down LDL cholesterol (the “bad” cholesterol) 2) the small interfering RNA (siRNA) inhibitor of PCSK9 likewise scales back levels of a slew of other atherogenic lipoproteins.
